tiprankstipranks
Defence Therapeutics Innovates in Cancer Radiotherapy
Company Announcements

Defence Therapeutics Innovates in Cancer Radiotherapy

Story Highlights

Defence Therapeutics (TSE:DTC) has released an update.

Don't Miss our Black Friday Offers:

Defence Therapeutics, a Canadian biotech firm, is advancing cancer treatment by developing a novel targeted Radio-Immuno-Conjugate (RIC) in partnership with the multinational nuclear company Orano. Their innovative RIC, which leverages Defence’s proprietary Accum technology, aims to deliver radioactivity directly to cancer cells while minimizing damage to healthy tissue. This cutting-edge approach could revolutionize cancer therapy by utilizing Auger electron emitters, previously unused due to their limitations.

For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics Welcomes New CSO to Drive Growth
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics Launches Convertible Debenture Offering
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics Welcomes Radiopharmaceutical Expert
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App